Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on LNTH stock, giving a Buy rating yesterday.Invest with Confidence: ...

Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal ...

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

LNTH Lantheus to Buy Evergreen Theragnostics Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its second acquisition this ...

Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen ...

Lantheus strengthens its radiopharmaceutical business with Evergreen and Life Molecular acquisitions, adding oncology and ...

Lantheus Holdings, Inc. (LNTH), a radiopharmaceutical company, experienced a 9% drop in its stock price on Tuesday after announcing a ...

On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...

Lantheus' oncology portfolio includes Pylarify (piflufolastat F 18) and a growing pipeline addressing various solid tumours.

Radiopharmaceutical specialist Lantheus Holdings (NASDAQ: LNTH) had some news to report Tuesday morning, but the market ...

Lantheus Holdings Inc., a radiopharmaceutical-focused company, has agreed to acquire Evergreen Theragnostics Inc., in an ...